Published in Blood Weekly, May 25th, 1998
The trial, which is placebo-controlled and double-blind, enrolls approximately 100 patients and is being conducted in 10 major cardiovascular centers in the U.S. by Berlex Laboratories, Inc., a subsidiary of Schering AG, Germany, in collaboration with Collateral Therapeutics, pursuant to a commercial Investigational New Drug application.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.